Leishmaniasis - Pipeline Insight, 2025: Advancing Antiparasitic Innovation Amidst Growing Global Health Focus | DelveInsight

Leishmaniasis, a neglected tropical disease caused by protozoan parasites of the genus Leishmania, remains a serious global health concern, especially in endemic regions across Asia, Africa, South America, and the Middle East. With high morbidity, limited treatment options, and growing resistance to traditional therapies like pentavalent antimonials, the need for novel, effective, and safer therapies has become more urgent than ever.

DelveInsight's "Leishmaniasis - Pipeline Insight, 2025" profiles more than 3+ pipeline candidates in development for cutaneous, visceral, and mucocutaneous forms of the disease. The landscape includes promising small molecules, immunotherapies, and repurposed drugs targeting parasite metabolism, immune modulation, and host-pathogen interactions. Leading the research front are companies and organizations like GSK, DNDi (Drugs for Neglected Diseases Initiative), IDRI, MedinCell, and Novartis, among others.

The report highlights ongoing clinical trials, innovative combination therapies, oral drug candidates, and injectable depot formulations designed to enhance access, compliance, and efficacy, particularly in resource-limited settings.

As global initiatives prioritize the elimination of leishmaniasis through improved treatment and surveillance, the therapeutic pipeline reflects a renewed momentum, moving toward safer, shorter, and more targeted treatment regimens to transform outcomes for millions affected globally.

Interested in learning more about the current treatment landscape and the key drivers shaping the leishmaniasis pipeline? Click here: https://www.delveinsight.com/report-store/leishmaniasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Leishmaniasis Pipeline Report
• DelveInsight's leishmaniasis pipeline analysis depicts a strong space with 2+ active players working to develop 3+ pipeline drugs for leishmaniasis treatment.
• The leading leishmaniasis companies include GlaxoSmithKline, Novartis Pharmaceuticals, and others are evaluating their lead assets to improve the leishmaniasis treatment landscape.
• Key leishmaniasis pipeline therapies in various stages of development include GSK3494245, LXE408, and others.
• As of April 2025, a clinical trial is underway at the University of Liverpool and the NHS Liverpool Clinical Research Facility to evaluate DNDI‐6899, another novel oral therapy for visceral leishmaniasis, aiming to improve accessibility and simplify treatment delivery.
• In April 2024, DNDi and partners initiated a Phase II study in Ethiopia investigating LXE408, an oral drug candidate for visceral leishmaniasis, designed to be safer, transportable, and more accessible than current injectable regimens

Request a sample and discover the recent breakthroughs happening in the leishmaniasis pipeline landscape at https://www.delveinsight.com/report-store/leishmaniasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Leishmaniasis Overview
Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania, transmitted to humans through the bite of infected female phlebotomine sandflies. The disease manifests in three primary forms-visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis (MCL)-each varying in severity and clinical presentation. Visceral leishmaniasis, also known as kala-azar, is the most severe form and can be fatal if left untreated, while cutaneous leishmaniasis leads to skin lesions and mucocutaneous leishmaniasis affects mucous membranes of the nose, mouth, and throat.

Leishmaniasis is endemic in over 90 countries, particularly in tropical and subtropical regions of Asia, Africa, the Americas, and southern Europe. The disease primarily affects impoverished communities with limited access to healthcare, making timely diagnosis and treatment challenging. Traditional treatments include pentavalent antimonials, amphotericin B, and miltefosine, but issues such as toxicity, resistance, and logistical barriers limit their widespread use.

In recent years, efforts to develop safer, oral, and more accessible therapies have accelerated. Innovations from organizations like the Drugs for Neglected Diseases initiative (DNDi) and emerging oral candidates like LXE408 and DNDI‐6899 are shaping a more hopeful treatment landscape. With increasing global health attention and partnerships driving R&D, the future outlook for effective and patient-friendly therapies in leishmaniasis is progressively improving.

Find out more about leishmaniasis medication at https://www.delveinsight.com/report-store/leishmaniasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Leishmaniasis Treatment Analysis: Drug Profile
LXE408: Appili Therapeutics
LXE408 is a first-in-class, parasite-selective proteasome inhibitor demonstrating potent and consistent activity against all kinetoplastid parasites, including Leishmania donovani and Leishmania infantum, the primary causative agents of visceral leishmaniasis. It also shows efficacy against other kinetoplastid diseases such as Chagas disease (T. cruzi) and human African trypanosomiasis (T. brucei). Safety data from healthy volunteer studies indicate that LXE408 is well-tolerated across all tested doses (up to 600 mg single and multiple doses). The drug is currently in Phase II clinical development for the treatment of visceral leishmaniasis.

Learn more about the novel and emerging leishmaniasis pipeline therapies at https://www.delveinsight.com/report-store/leishmaniasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Leishmaniasis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Leishmaniasis Pipeline Report
• Coverage: Global
• Key Leishmaniasis Companies: GlaxoSmithKline, Novartis Pharmaceuticals, and others.
• Key Leishmaniasis Pipeline Therapies: GSK3494245, LXE408, and others.

Dive deep into rich insights for drugs used for leishmaniasis treatment, visit: https://www.delveinsight.com/report-store/leishmaniasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Leishmaniasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Leishmaniasis Pipeline Therapeutics
6. Leishmaniasis Pipeline: Late-Stage Products (Phase III)
7. Leishmaniasis Pipeline: Mid-Stage Products (Phase II)
8. Leishmaniasis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.